Celltrion's Remsima Posts 1 Trillion Won Sales for 2nd Year...Betting on Liquid Formulation This Year

Global sales reach 1.0495 trillion won...driven by expanded prescriptions in Europe
Remsima SC nears 1 trillion won...boosted by dual formulation strategy
Liquid formulation to be rolled out sequentially across Europe, starting in Northern Europe

Celltrion's autoimmune disease treatment "Remsima (infliximab)" has surpassed 1 trillion won in annual sales for the second consecutive year, cementing its status as a global blockbuster. With the subcutaneous (SC) formulation "Remsima SC" also on the verge of breaking through 1 trillion won in sales, Celltrion plans to further boost this year's growth momentum by sequentially launching the first liquid formulation in the infliximab class in Europe.

Celltrion announced on February 10, 2026 that Remsima's global sales last year reached approximately 1.0495 trillion won, marking the second consecutive year that its annual sales exceeded 1 trillion won. The company explained that it was able to achieve sales of more than 1 trillion won thanks to increased prescriptions worldwide and the expansion of the infliximab market in Europe. Global sales of Remsima SC also climbed about 40% year-on-year from 600.7 billion won to 839.4 billion won, putting it on the brink of surpassing 1 trillion won. There is growing expectation that, following Remsima, it could become the second "blockbuster drug" originating from Korea.

Celltrion Remsima. Celltrion

The expansion of the infliximab market in Europe appears to have had a positive impact on Remsima's sales performance. From 2019 to 2024, over a six-year period, the European infliximab market recorded an average annual growth rate of about 9 percentage points. Since COVID-19, demand has increased for subcutaneous (SC) formulations that can be conveniently self-administered, and this has driven the growth in Remsima SC prescriptions. Celltrion stated, "After switching from competing infliximab products to Remsima and then converting to Remsima SC, we have seen a dual formulation effect, which has boosted sales of both products."

As of the third quarter of last year, Remsima has been leading the market in Europe, with market shares of 62% in the United Kingdom, 49% in Spain, and 48% in Germany among the five major EU countries, and with high shares in other European countries as well, including 75% in Ireland and 64% in Austria. Remsima SC also surpassed a 30% market share for the first time in the EU5. In the United States, "Zymfentra" (the U.S. brand name for Remsima SC), which was launched as a new drug, has recorded an average monthly prescription growth rate of 31% since sales began in March 2024, continually setting new highs in weekly prescription volumes.

The new liquid formulation to be added this year is expected to become a fresh growth driver for Remsima. Compared with the existing lyophilized formulation, the liquid formulation can reduce preparation time by more than 50% and cut costs such as labor and consumables to around 20% of current levels. Because it does not require storage equipment to maintain a frozen state, it can also reduce storage space and storage fees by up to 70%. Celltrion plans to begin sequentially launching the liquid formulation of Remsima across Europe, starting in Northern Europe at the end of this month.

A Celltrion official said, "As Remsima, which has surpassed 1 trillion won in annual sales for two consecutive years, continues to firmly maintain its position as a global blockbuster therapy, the liquid formulation is attracting significant attention from the European medical community even before its launch, raising expectations for its successful market penetration," adding, "This year, following Remsima, we will do our utmost in marketing and sales activities worldwide so that the rapidly growing Remsima SC can emerge as the 'second global blockbuster drug from Korea'."

This content was produced with the assistance of AI translation services.